April 29, 2022
24 min listen
Save
Ocushield: Blue Light Blocking Filters in the Eye Care Practice
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light.
- Intro :01
- Dr. Patel’s introduction and background :43
- The science and necessity behind blue light blocking filters 5:35
- Short-term effects of blue light on the eyes 7:15
- Long-term effects of blue light on the eyes 8:24
- Are eye care professionals doing enough to promote blue light protection? 12:11
- Has the pandemic affected the demand/awareness of blue light related products? 14:25
- Ocushield filters: what they are and how to get them 16:15
- What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03
- How to contact Dr. Patel and Ocushield 20:31
- Dr. Patel’s final thoughts on our visual system and the importance of protecting it 21:11
- Outro 22:01
Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at www.ocushield.com. Follow him on Instagram, Facebook and Twitter @getocushield.
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
